Skip to main content
. 2024 Dec 19;20:564. doi: 10.1186/s12917-024-04420-1

Table 1.

Results of anthelmintics resistance tests

Area Anthelmintic n Pre-Treatment EPG (Mean ± sd) 14th Day Post-Treatment EPG (Mean ± sd) FECR (%) Guidelines: clinical Guidelines: research
Horqin Right Wing Front Banner Closantel 120 1679 ± 2860 110 ± 192 86.2 Low Resistant Resistant
Ivermectin 120 1848 ± 2424 817 ± 1833 53.99 Resistant Resistant
Albendazole 120 1460 ± 2259 390 ± 589 70.12 Resistant Resistant
Levamisole 120 1545 ± 2121 71 ± 149 91.81 Low Resistant Resistant
Control 120 1430 ± 1631 1410 ± 1982 0.53 - -
Horqin Right Wing Middle Banner Closantel 66 2813 ± 4186 70 ± 158 96.89 Low Resistant Low Resistant
Ivermectin 66 2970 ± 3801 1755 ± 1894 23.87 Resistant Resistant
Albendazole 66 2201 ± 3331 962 ± 1659 35.55 Resistant Resistant
Levamisole 66 1965 ± 2495 129 ± 341 94.73 Resistant Resistant
Control 66 1885 ± 1797 1684 ± 1532 -18.84 - -
Jalaid Banner Closantel 54 1127 ± 1256 145 ± 189 84.18 Resistant Resistant
Ivermectin 54 894 ± 725 772 ± 1159 14.72 Resistant Resistant
Albendazole 54 1013 ± 703 670 ± 580 28.61 Resistant Resistant
Levamisole 54 1014 ± 1116 113 ± 168 85.01 Resistant Resistant
Control 54 932 ± 903 919 ± 679 -7.12 - -
Ulanhot city Closantel 60 1210 ± 2131 39 ± 62 94.68 Low Resistant Resistant
Ivermectin 60 927 ± 914 338 ± 314 55.61 Resistant Resistant
Albendazole 60 856 ± 663 305 ± 319 58.49 Resistant Resistant
Levamisole 60 907 ± 1115 67 ± 367 91.91 Resistant Resistant
Control 60 899 ± 699 1058 ± 1245 -20.18 - -
Tuquan County Closantel 54 1506 ± 2096 164 ± 238 87.16 Resistant Resistant
Ivermectin 54 1876 ± 4489 1188 ± 2489 27.85 Resistant Resistant
Albendazole 54 2346 ± 4662 693 ± 1060 57.13 Resistant Resistant
Levamisole 54 1739 ± 2186 181 ± 571 88.87 Resistant Resistant
Control 54 1435 ± 1882 1420 ± 1924 -6.19 - -

Citations: EPG (Egg Per Gram), FECR (Fecal Egg Count Reduction)

Guidelines (clinical): Based on an expected efficacy of 99% and a lower efficacy threshold of 90%

Guidelines (research): Based on an expected efficacy of 99% and a lower efficacy threshold of 95%